Ovarian Cancer Market Size, Share, Trends, Industry Analysis Report: By Type, Treatment Type, End User, and Region

Description

List of Tables

The ovarian cancer market size is expected to reach USD 35.00 billion by 2034, according to a new study by Polaris Market Research. The report "Ovarian Cancer Market Size, Share, Trends, Industry Analysis Report: By Type (Epithelial Ovarian Cancer, Germ Cell Ovarian Cancer, and Stromal Cell Ovarian Cancer), Treatment Type, End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Ovarian cancer is a type of cancer that originates in the ovaries, where abnormal cell growth leads to the formation of tumors. It is one of the most common and lethal cancers affecting women, often diagnosed at an advanced stage due to its subtle symptoms. The ovarian cancer market growth is attributed to advancements in treatment options, including chemotherapy, targeted therapies, and immunotherapy. Key drivers of this growth include increasing awareness, rising prevalence, and the demand for personalized medicine and early detection tools.

Ovarian cancer market opportunities lie in the development of novel therapies and improving patient access, particularly in emerging markets. Trends such as the growing use of combination therapies, clinical trials, and a focus on biomarker-driven treatments are shaping the future of the market, with ongoing research and development expected to fuel continued expansion.

Ovarian Cancer Market Report Highlights

The epithelial ovarian cancer segment, by type, dominated the ovarian cancer market share in 2024 due to the high demand for targeted therapies and chemotherapy.
By treatment type, chemotherapy remains the largest segment in the market due to its widespread use in first-line and recurrent treatment.
North America dominated the ovarian cancer market revenue share in 2024, supported by advanced healthcare infrastructure and high treatment adoption rates. However, Asia Pacific is experiencing the fastest growth, fueled by increasing cancer awareness and healthcare improvements in emerging countries.
A few key players in the ovarian cancer market include Bristol-Myers Squibb Company; AstraZeneca PLC; Roche Holding AG; Merck & Co., Inc.; GlaxoSmithKline plc; Eli Lilly and Company; Pfizer Inc.; Novartis AG; AbbVie Inc.; Amgen Inc.; Clovis Oncology, Inc.; Gilead Sciences, Inc.; Sanofi S.A.; Teva Pharmaceutical Industries Ltd.; and Bayer AG.

Polaris Market Research has segmented the ovarian cancer market report on the basis of type, treatment type, end user, and region:

By Type Outlook (Revenue - USD Billion, 2020-2034)

Epithelial Ovarian Cancer
Germ Cell Ovarian Cancer
Stromal Cell Ovarian Cancer

By Treatment Type Outlook (Revenue - USD Billion, 2020-2034)

Immunotherapy
Chemotherapy
Targeted Therapy
Surgery
Others

By End User Outlook (Revenue - USD Billion, 2020-2034)

Hospitals
Homecare
Specialty Centre
Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

Product Code: PM1369

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source

4. Global Ovarian Cancer Market Insights

4.1. Ovarian Cancer Market - Market Snapshot
4.2. Ovarian Cancer Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.2. Restraints and Challenges
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Ovarian Cancer Market Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Ovarian Cancer Market, by Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
5.3. Epithelial Ovarian Cancer
- 5.3.1. Global Ovarian Cancer Market, by Epithelial Ovarian Cancer, by Region, 2020-2034 (USD Billion)
5.4. Germ Cell Ovarian Cancer
- 5.4.1. Global Ovarian Cancer Market, by Germ Cell Ovarian Cancer, by Region, 2020-2034 (USD Billion)
5.5. Stromal Cell Ovarian Cancer
- 5.5.1. Global Ovarian Cancer Market, by Stromal Cell Ovarian Cancer, by Region, 2020-2034 (USD Billion)

6. Global Ovarian Cancer Market, by Treatment

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
6.3. Immunotherapy
- 6.3.1. Global Ovarian Cancer Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
6.4. Chemotherapy
- 6.4.1. Global Ovarian Cancer Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
6.5. Targeted Therapy
- 6.5.1. Global Ovarian Cancer Market, by Targeted Therapy, by Region, 2020-2034 (USD Billion)
6.6. Surgery
- 6.6.1. Global Ovarian Cancer Market, by Surgery, by Region, 2020-2034 (USD Billion)
6.7. Others
- 6.7.1. Global Ovarian Cancer Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Ovarian Cancer Market, by End-user

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
7.3. Hospitals
- 7.3.1. Global Ovarian Cancer Market, by Hospitals, by Region, 2020-2034 (USD Billion)
7.4. Homecare
- 7.4.1. Global Ovarian Cancer Market, by Homecare, by Region, 2020-2034 (USD Billion)
7.5. Speciality Centre
- 7.5.1. Global Ovarian Cancer Market, by Speciality Centre, by Region, 2020-2034 (USD Billion)
7.6. Others
- 7.6.1. Global Ovarian Cancer Market, by Others, by Region, 2020-2034 (USD Billion)

8. Global Ovarian Cancer Market, by Geography

8.1. Key Findings
8.2. Introduction
- 8.2.1. Ovarian Cancer Market Assessment, By Geography, 2020-2034 (USD Billion)
8.3. Ovarian Cancer Market - North America
- 8.3.1. North America: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
- 8.3.2. North America: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
- 8.3.3. North America: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.3.4. Ovarian Cancer Market - U.S.
  - 8.3.4.1. U.S.: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.3.4.2. U.S.: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.3.4.3. U.S.: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.3.5. Ovarian Cancer Market - Canada
  - 8.3.5.1. Canada: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.3.5.2. Canada: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.3.5.3. Canada: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
8.4. Ovarian Cancer Market - Europe
- 8.4.1. Europe: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
- 8.4.2. Europe: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
- 8.4.3. Europe: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.4.4. Ovarian Cancer Market - UK
  - 8.4.4.1. UK: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.4.2. UK: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.4.3. UK: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.4.5. Ovarian Cancer Market - France
  - 8.4.5.1. France: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.5.2. France: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.5.3. France: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.4.6. Ovarian Cancer Market - Germany
  - 8.4.6.1. Germany: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.6.2. Germany: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.6.3. Germany: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.4.7. Ovarian Cancer Market - Italy
  - 8.4.7.1. Italy: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.7.2. Italy: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.7.3. Italy: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.4.8. Ovarian Cancer Market - Spain
  - 8.4.8.1. Spain: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.8.2. Spain: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.8.3. Spain: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.4.9. Ovarian Cancer Market - Netherlands
  - 8.4.9.1. Netherlands: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.9.2. Netherlands: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.9.3. Netherlands: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.4.10. Ovarian Cancer Market - Russia
  - 8.4.10.1. Russia: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.10.2. Russia: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.10.3. Russia: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.4.11. Ovarian Cancer Market - Rest of Europe
  - 8.4.11.1. Rest of Europe: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.4.11.2. Rest of Europe: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.4.11.3. Rest of Europe: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
8.5. Ovarian Cancer Market - Asia Pacific
- 8.5.1. Asia Pacific: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.5.4. Ovarian Cancer Market - China
  - 8.5.4.1. China: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.4.2. China: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.4.3. China: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.5.5. Ovarian Cancer Market - India
  - 8.5.5.1. India: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.5.2. India: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.5.3. India: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.5.6. Ovarian Cancer Market - Malaysia
  - 8.5.6.1. Malaysia: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.6.2. Malaysia: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.6.3. Malaysia: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.5.7. Ovarian Cancer Market - Japan
  - 8.5.7.1. Japan: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.7.2. Japan: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.7.3. Japan: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.5.8. Ovarian Cancer Market - Indonesia
  - 8.5.8.1. Indonesia: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.8.2. Indonesia: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.8.3. Indonesia: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.5.9. Ovarian Cancer Market - South Korea
  - 8.5.9.1. South Korea: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.9.2. South Korea: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.9.3. South Korea: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.5.10. Ovarian Cancer Market - Australia
  - 8.5.10.1. Australia: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.10.2. Australia: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.10.3. Australia: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.5.11. Ovarian Cancer Market - Rest of Asia Pacific
  - 8.5.11.1. Rest of Asia Pacific: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.5.11.2. Rest of Asia Pacific: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.5.11.3. Rest of Asia Pacific: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
8.6. Ovarian Cancer Market - Middle East & Africa
- 8.6.1. Middle East & Africa: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.6.4. Ovarian Cancer Market - Saudi Arabia
  - 8.6.4.1. Saudi Arabia: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.6.4.2. Saudi Arabia: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.6.4.3. Saudi Arabia: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.6.5. Ovarian Cancer Market - UAE
  - 8.6.5.1. UAE: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.6.5.2. UAE: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.6.5.3. UAE: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.6.6. Ovarian Cancer Market - Israel
  - 8.6.6.1. Israel: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.6.6.2. Israel: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.6.6.3. Israel: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.6.7. Ovarian Cancer Market - South Africa
  - 8.6.7.1. South Africa: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.6.7.2. South Africa: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.6.7.3. South Africa: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.6.8. Ovarian Cancer Market - Rest of Middle East & Africa
  - 8.6.8.1. Rest of Middle East & Africa: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.6.8.2. Rest of Middle East & Africa: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.6.8.3. Rest of Middle East & Africa: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
8.7. Ovarian Cancer Market - Latin America
- 8.7.1. Latin America: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
- 8.7.2. Latin America: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
- 8.7.3. Latin America: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.7.4. Ovarian Cancer Market - Mexico
  - 8.7.4.1. Mexico: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.7.4.2. Mexico: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.7.4.3. Mexico: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.7.5. Ovarian Cancer Market - Brazil
  - 8.7.5.1. Brazil: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.7.5.2. Brazil: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.7.5.3. Brazil: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.7.6. Ovarian Cancer Market - Argentina
  - 8.7.6.1. Argentina: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.7.6.2. Argentina: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.7.6.3. Argentina: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)
- 8.7.7. Ovarian Cancer Market - Rest of Latin America
  - 8.7.7.1. Rest of Latin America: Ovarian Cancer Market, by Type, 2020-2034 (USD Billion)
  - 8.7.7.2. Rest of Latin America: Ovarian Cancer Market, by Treatment, 2020-2034 (USD Billion)
  - 8.7.7.3. Rest of Latin America: Ovarian Cancer Market, by End-user, 2020-2034 (USD Billion)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. Bristol-Myers Squibb Company
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. AstraZeneca PLC
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. Roche Holding AG
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. Merck & Co., Inc.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. GlaxoSmithKline plc
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. Eli Lilly and Company
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. Pfizer Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. Novartis AG
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. AbbVie Inc.
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. Amgen Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development